NewYork-Presbyterian and its partner medical schools are putting an AI assistant in the virtual back pocket of clinicians across New York City and Westchester, rolling out OpenEvidence as a systemwide clinical search and decision-support tool. Hospital leaders say the platform is meant to give doctors rapid, research-backed answers at the point of care and to help turn fresh studies into everyday treatment decisions, at a time when health systems are moving fast to plug vetted AI tools into routine practice.
In a press release via Business Wire, OpenEvidence said the deployment will extend across all NewYork-Presbyterian hospitals and care sites and will also be available to clinical staff at Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine. According to the release, clinicians will be able to ask complex medical questions in plain, conversational language and get answers grounded in peer-reviewed research and clinical guidelines. The company lists its headquarters in Miami and names Daniel Nadler as CEO.
Why This Matters Now
The timing lines up with a run of recent regulatory wins for clinical AI. NewYork-Presbyterian and its partners reported that an ECG-based screening model developed with Columbia received FDA clearance on June 23, and that Pathway Labs has arranged to license that technology to OpenEvidence so it can be made broadly available. Reporting from STAT describes the clearance and the planned licensing, a pairing advocates say is meant to shrink the gap between validation and bedside use by tying a high-profile FDA decision to a tool clinicians already consult.
What OpenEvidence Does
OpenEvidence is pitched as an evidence search engine and clinical decision-support system that returns cited summaries, guideline references and links to underlying studies for use at the point of care. Earlier this year, the company reported hitting a milestone of one million clinician consultations in a single day, a number it points to as evidence of day-to-day uptake among medical professionals. A March release from PR Newswire and the July announcement both highlight evidence sourcing and clear citation as core selling points.
How Clinicians Will Use It
NewYork-Presbyterian chief information officer Chif Umejei said the system is intended to help clinicians "access and analyze medical research in real time," while OpenEvidence chief medical officer Dr. Travis Zack framed the rollout as giving "every clinician... equal access to the best available evidence," according to the press release on Business Wire. Whether it actually feels that seamless on a busy ward will be the real-world test.
Local Impact
Hospital leaders say the deployment could be most noticeable in community clinics and outpatient practices, where clinicians often do not have immediate access to specialty literature even though they are facing complex decisions. Because NewYork-Presbyterian’s network stretches from major academic hospitals to neighborhood sites across all five boroughs and into Westchester, they argue that tools validated at academic centers can reach everyday care more quickly. At the same time, clinicians and policy experts continue to stress that local validation, training and ongoing monitoring are essential to avoid unexpected errors or bias, a point reflected in materials from NewYork-Presbyterian. The health system’s scale and partnerships position it as a potentially important distribution channel for future FDA-cleared algorithms, if they prove themselves in practice.
What To Watch
Observers will be looking to see whether NewYork-Presbyterian publishes real-world safety and performance data, how quickly FDA-cleared tools like EchoNext are folded into everyday workflows and what kind of training accompanies the rollout. For clinicians, the bottom line will be whether OpenEvidence genuinely speeds up decision-making and keeps the focus on patients, instead of adding a new layer of digital busywork or risk.
